Skip to main content

Table 3 Patient and tumor characteristics by a total dose of external beam radiation therapy (EBRT) alone

From: Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer

  <70 Gy 70–74 Gy 75+ Gy
Characteristics (%)* Patients (n) (%)* Patients (n) (%)* Patients (n)
Total, n = 4611 (1636) 53.0 2444 (920) 25.0 1152 (382) 22.0 1015 (334)
States (p < 0.0001)§       
  A 32.2 369 (100) 41.5 476 (125) 26.3 302 (69)
  B 74.3 645 (293) 9.8 85 (39) 15.9 138 (69)
  C 58.5 204 (57) 27.5 96 (28) 14.0 49 (13)
  D 57.7 253 (166) 26.7 117 (78) 15.6 68 (45)
  E 46.2 188 (74) 13.0 53 (19) 40.8 167 (48)
  F 59.5 584 (157) 22.4 221 (52) 18.1 177 (50)
  G 48.0 201 (73) 24.8 104 (41) 27.2 114 (40)
Age (y) (p = 0.0156)§       
  20–59 64.6 345 (131) 15.2 81 (33) 20.2 108 (37)
  60–69 53.5 837 (338) 25.5 400 (141) 21.0 330 (127)
  70+ 50.3 1262 (451) 26.7 671 (208) 23.0 577 (170)
Race (p < 0.0001)§       
  White, non-hispanic (NH) 53.5 1706 (508) 24.4 777 (190) 22.1 703 (183)
  Black, NH 59.8 603 (332) 21.2 213 (123) 19.0 191 (106)
  Hispanic 32.1 93 (52) 38.8 112 (38) 29.1 84 (23)
  Asians/others 32.9 42 (28) 38.5 50 (31) 28.6 37 (22)
Marital status (p = 0.8262)§       
  Single 55.0 586 (238) 23.8 253 (92) 21.2 225 (84)
  Married 53.2 1773 (649) 23.8 795 (263) 23.0 766 (243)
Education (p = 0.0279)§       
  Not undereducated 50.8 1417 (481) 24.6 685 (200) 24.6 688 (195)
  Undereducated 56.3 1014 (435) 25.8 464 (181) 17.9 323 (138)
Working class (p = 0.0910)§       
  Not working class 48.9 908 (312) 26.3 487 (133) 24.8 461 (127)
  Working class 55.7 1522 (604) 24.2 662 (248) 20.1 550 (206)
Urbanization (p = 0.0293)§       
  Urban 47.6 1023 (400) 28.3 608 (200) 24.1 519 (165)
  Rural 57.4 454 (165) 22.7 179 (64) 19.9 157 (57)
  Urban-Rural mix 57.8 954 (351) 21.9 362 (117) 20.3 335 (111)
Poverty level (p = 0.0255)§       
  Not in poverty level 51.6 1870 (644) 24.9 904 (268) 23.5 852 (254)
  In poverty level 58.1 561 (272) 25.4 245 (113) 16.5 159 (79)
Health insurance (p = 0.0036)§       
  Not insured 58.7 46 (22) 22.7 18 (6) 18.6 14 (7)
  Public coverage 56.9 1732 (664) 20.9 637 (229) 22.2 674 (232)
  Private coverage 45.1 519 (179) 36.4 418 (117) 18.5 212 (65)
  Insurance, NOS 61.6 87 (33) 16.5 23 (11) 21.9 31 (10)
Piccirillo comorbidity score (p = 0.0800)§       
  None 50.5 613 (221) 25.5 310 (94) 24.0 291 (88)
  Mild 52.2 1273 (492) 24.8 604 (213) 23.0 560 (188)
  Moderate 60.3 378 (143) 19.1 120 (44) 20.6 129 (42)
  Severe 65.1 119 (46) 23.4 43 (11) 11.5 21 (10)
PSA (ng/ml) (p = 0.0016)§       
  <10 50.0 1446 (533) 27.3 787 (256) 22.7 656 (210)
  10–20 53.7 556 (215) 21.2 220 (74) 25.1 259 (81)
  >20 65.1 408 (158) 21.0 131 (49) 13.9 87 (40)
Clinical T stage (p = 0.1833)§       
  Tx-T0 26.1 9 (4) 24.3 9 (4) 49.6 18 (5)
  T1 52.1 1477 (569) 26.2 741 (252) 21.7 613 (197)
  T2 53.7 825 (299) 24.4 376 (115) 21.9 336 (115)
  T3-T4 64.4 133 (48) 12.8 26 (11) 22.8 47 (17)
Gleason score (p = 0.0007)§       
  2–6 46.9 1033 (385) 30.5 670 (218) 22.6 498 (163)
  7 57.6 958 (361) 20.5 341 (115) 21.9 365 (119)
  8–10 61.4 441 (169) 17.8 128 (46) 20.8 150 (50)
Recurrence risk group (p = 0.0001)§       
  LR 44.3 620 (229) 34.0 477 (155) 21.7 304 (101)
  IR 53.8 1071 (401) 21.9 435 (143) 24.3 484 (150)
  HR 61.8 753 (290) 19.7 241 (84) 18.5 226 (83)
  1. LR, low risk group; IR, intermediate risk group; HR, high/very high risk group.
  2. (*) Row percentages based on weighted number of patients.
  3. (†) Weighted number of patients, with unweighted number in parentheses.
  4. (‡) Excluded 101 patients (unweighted) who did not have information on EBRT dose.
  5. (§) p-values (Chi-square test to measure of association between EBRT dose and each of socio-demographic/clinical variables).